What is the Return on Assets (ROA) of Agenus this year?
The Return on Assets (ROA) of Agenus is -0.78 undefined this year.
Agenus ROA 2024
Agenus ROA
-0.78
Ticker
AGEN
ISIN
US00847G7051
WKN
A1JLKZ
In 2024, Agenus's return on assets (ROA) was -0.78, a 47.1% increase from the -0.53 ROA in the previous year.
Agenus Aktienanalyse
What does Agenus do?
Agenus Inc is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus started as a small start-up company focusing on the research of antibodies against chronic viral diseases. In 2000, the company developed the first approved therapeutic vaccine against cervical cancer in collaboration with GlaxoSmithKline. Since then, Agenus has expanded its business to the discovery, development, and commercialization of novel antibody and immunotherapies. The company has brought many groundbreaking medications to the market, including a cancer immunotherapy called Prophage, which is approved for the treatment of glioblastoma, an aggressive brain tumor. Agenus' business model focuses on the development of immunotherapies that utilize the body's immune system to fight against cancer or other diseases. The company's research and development programs are divided into three areas: antibody development, immunotherapy, and preclinical developments. Agenus has a comprehensive library of antibodies and utilizes them to develop new and innovative antibodies and antibody conjugates that can be used to treat cancer and autoimmune diseases. The company has also developed a range of immunotherapies aimed at supporting the body's immune system in fighting against cancer and other diseases, including therapies targeting checkpoint inhibitors that enhance the body's immune response to cancer cells. In addition, Agenus has a broad portfolio of preclinical programs aimed at developing new drugs and therapies for the treatment of cancer and other diseases. Agenus has introduced a range of products to the market that can be used for the treatment of cancer and other diseases, including Prophage, a personalized cancer vaccine tailored to each patient for the treatment of glioblastoma. Other products include Zalifrelimab, a checkpoint inhibitor that aims to enhance the body's immune response to cancer, INCAGN2385, another checkpoint inhibitor that enhances T-cell activity in the body, and INCAGN1949, an antibody therapy targeting the GITR protein that can help enhance the immune response against cancer cells. In summary, Agenus is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company has a long history in antibody research and development and has expanded its efforts to develop immunotherapies. Agenus has a comprehensive library of antibodies and has introduced a range of products to the market for the treatment of cancer and other diseases. With a broad portfolio of products and preclinical programs, Agenus remains a key player in the field of immunotherapies and is expected to drive further groundbreaking developments in the future. Agenus ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Agenus's Return on Assets (ROA)
Agenus's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Agenus's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Agenus's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Agenus’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Agenus stock
What was the ROA of Agenus compared to the previous year?
The ROA of Agenus has increased by 47.1% compared to the previous year.
What consequences do high ROA have for investors of Agenus?
A high ROA is advantageous for investors of Agenus, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Agenus?
A low ROA can be unfavorable for investors of Agenus as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Agenus affect the company?
An increase in ROA of Agenus can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Agenus impact the company?
A reduction in the ROA of Agenus can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Agenus?
Some factors that can influence the ROA of Agenus include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Agenus important for investors?
The ROA of Agenus is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Agenus take to improve ROA?
To improve ROA, Agenus can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Agenus pay?
Over the past 12 months, Agenus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agenus is expected to pay a dividend of 0 USD.
What is the dividend yield of Agenus?
The current dividend yield of Agenus is .
When does Agenus pay dividends?
Agenus pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Agenus?
Agenus paid dividends every year for the past 0 years.
What is the dividend of Agenus?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Agenus located?
Agenus is assigned to the 'Health' sector.
Wann musste ich die Aktien von Agenus kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Agenus from 8/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/25/2024.
When did Agenus pay the last dividend?
The last dividend was paid out on 8/25/2024.
What was the dividend of Agenus in the year 2023?
In the year 2023, Agenus distributed 0 USD as dividends.
In which currency does Agenus pay out the dividend?
The dividends of Agenus are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Agenus
Our stock analysis for Agenus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agenus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
